DNAtrix Announces Oral Presentation of Positive Overall Survival Data With DNX-2401 in DIPG at the Society for Neuro-Oncology (SNO) Annual Meeting
UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced that data from the Phase 1 study of DNX-2401 in diffuse intrinsic pontine glioma (DIPG) was presented in an oral presentation at the 26th Annual Meeting and Education Day of the Society for Neuro-oncology (SNO), which was held from November 18-21, 2021 in Boston, MA.
DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer
UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced the appointment of David Liebowitz, M.D., Ph.D., an industry veteran with over 20 years of experience in oncology drug and viral vaccine development, as chief medical officer.
DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors Published in Clinical Cancer Research
UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced preclinical data evaluating the use of DNX-2401 against the pediatric brain malignancies atypical teratoid/rhabdoid tumor (AT/RT) and primitive neuroectodermal tumors (PNETs) was published in Clinical Cancer Research.
DNAtrix Presents Positive Results From Study at the 2019 SNO Annual Meeting
UF startup DNAtrix, a leader in the development of oncolytic viruses for cancer therapy, presented updated safety and efficacy data from the fully-enrolled... Read More
DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial (PR Newswire)
UF startup DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced the treatment of the first patient with DNX-2440, an oncolytic... Read More
Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma Shows Remarkable Results (Onco’zine)
Preliminary results from the CAPTIVE / KEYNOTE-192 study (NCT02798406) dose escalation study evaluating a single intratumoral injection of DNX-2401 (tasadenoturev; UF startup... Read More
